An update on anaphylaxis and urticaria

Notable scientific developments have taken place in the field of anaphylaxis and urticaria in recent years; they are highlighted in this review. Case-control studies, genome-wide association studies, and large omics analyses have promoted further insights into not only the underlying genetics but also the biomarkers of both anaphylaxis and urticaria. New evidence regarding IgE-dependent and non-IgE-dependent mechanisms of anaphylaxis and urticaria, including the Mas-related G protein-coupled receptor (MRGPR [formerly MRG]) signaling pathway, has been gained. Putative elicitors of anaphylactic reactions in the context of coronavirus disease 2019 (COVID-19) vaccination and impact of the COVID-19 pandemic on the management and course of chronic urticaria have been reported. Clinical progress has also been made regarding the severity grading and risk factors of anaphylaxis, as well as the distinction of phenotypes and elicitors of both diseases. Furthermore, novel treatment approaches for anaphylaxis and subtypes of urticaria have been assessed, with different outcome and potential for a better disease control or prevention.

Automated summary

Significant progress has been made in the field of anaphylaxis and urticaria in recent years. Studies have provided insights into the genetic and biomarker aspects of these conditions, as well as their IgE-dependent and non-IgE-dependent mechanisms. The potential triggers of anaphylactic reactions related to COVID-19 vaccination and the impact of the COVID-19 pandemic on chronic urticaria have been reported. Clinical advancements include severity grading and risk factors for anaphylaxis, as well as the distinction of phenotypes and triggers for both conditions. Novel treatment approaches for anaphylaxis and different subtypes of urticaria have been evaluated.